What is the 13F Pro Quality Score for PLX?

13F Pro ranks Protalix BioTherapeutics, Inc. (PLX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PLX's current score at https://13fpro.ai/research/PLX (free sign-up required for the full ranking).

Which hedge funds own the most PLX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PLX include BlackRock,, MAK CAPITAL ONE, RENAISSANCE TECHNOLOGIES. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PLX as soon as new 13F filings post.

Where does 13F Pro source PLX data?

All Protalix BioTherapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Protalix BioTherapeutics, Inc. files with the SEC under CIK 1006281. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PLX in?

Protalix BioTherapeutics, Inc. (PLX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives PLX's revenue?

Per Protalix BioTherapeutics, Inc.'s latest 10-Q filed with the SEC on 2026-05-13, the biggest revenue drivers are: Product Sales ($7.419M, -26% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/PLX.

What are PLX's largest expenses?

Protalix BioTherapeutics, Inc.'s latest 10-Q reports these as the largest expense items: Research and Development ($5.426M, +56% YoY); Cost of Revenues ($4.127M, -50% YoY); Selling, General, and Administrative ($3.051M, +17% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is PLX research updated on 13F Pro?

PLX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Protalix BioTherapeutics, Inc.(PLX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1006281 PLX stock profile & AI dashboard →

13F Pro Quality Score

67.0/100

Rank #488 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

74.2/100

Profitability

88.7/100

Balance Sheet

97.2/100

Earnings Quality

77.9/100

Free Cash Flow

57.7/100

Institutional Flow

72.6/100

Revenue Scale

14.8/100

Dilution Risk

27.8/100

PLX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Protalix BioTherapeutics, Inc. (PLX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PLX at 67.0/100 on a 32-signal composite quality model, placing it at rank #488 of 2,879 stocks — the top 25% of the AI-ranked universe. PLX scores in the top quartile across balance sheet strength (97.2), profitability (88.7), earnings quality (77.9). Areas of concern include revenue scale (14.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 27.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Protalix BioTherapeutics, Inc. reports quarterly revenue of $33.8M, net income of $18.3M, free cash flow of $21.3M. Top institutional holders of PLX by reported 13-F value include BlackRock,, MAK CAPITAL ONE, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. PLX trades on the NYSE exchange and files with the SEC under CIK 1006281. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PLX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Protalix BioTherapeutics, Inc. directly from SEC EDGAR. Protalix BioTherapeutics, Inc.'s 13F Pro composite quality score has ranged between 12 and 67 since 2021, currently 67.0 — an improving long-term trajectory across 30 quarterly and live scoring snapshots.

✦

Fun facts about Protalix BioTherapeutics, Inc.

Quirks, history, and lore behind PLX — the kind of stuff that makes a stock memorable.

1
The Basics
A biopharmaceutical company · micro-cap · listed on NYSE American · headquartered in Israel with a U.S. presence.
2
The Numbers
Annual revenues in the tens of millions of dollars — modest by pharma standards — driven almost entirely by a single approved enzyme replacement therapy.
3
The History
Founded in the early 2000s, it pioneered a platform for growing therapeutic proteins inside plant cells rather than in traditional mammalian cell cultures.
4
The Secret
Its secret weapon is a carrot cell bioreactor system — yes, carrots — used to manufacture drugs for rare lysosomal storage disorders.
5
The Lore
It won FDA approval for taliglucerase alfa, the first plant-cell-derived therapeutic protein ever approved, offering an alternative for patients with Gaucher disease.
6
The Giveaway
An Israeli biotech that grows Gaucher disease medicine in carrot cells, trades under the ticker PLX, and proved that plants could be a serious drug factory.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving PLX's Business? Latest 10-Q Breakdown

AI-extracted from Protalix BioTherapeutics, Inc.'s 10-Q filed 2026-05-13 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Protalix swung to $18.3M net income in Q1 2026, driven by a $25.0M Chiesi milestone payment for EU approval of Elfabrio's 2mg/kg dosage.

Biggest Revenue Drivers

Product Sales$7.419M-26% YoY

Comprised of Pfizer Gaucher sales, Fiocruz Brazil sales, and Chiesi Fabry sales; decrease driven by timing of Pfizer purchases and Fiocruz deliveries.

Largest Expense Items

Research and Development$5.426M+56% YoY

Increase resulted primarily from preparations for and initiation of RELEASE study.

Cost of Revenues$4.127M-50% YoY

Decrease resulted from lower sales to Pfizer and Fiocruz, partially offset by Chiesi sales increase.

Selling, General, and Administrative$3.051M+17% YoY

Increase resulted primarily from $0.4M rise in salary and related expenses.

Watch Items from the Filing

Chiesi milestone dependency: $25.0M of Q1 revenue came from single Chiesi milestone; company expects minimal future license/R&D services revenue now that Elfabrio clinical development is complete.
Customer concentration in product sales: Pfizer represented 20% of Q1 2026 product revenue ($1.452M vs $6.979M YoY), driven by timing of purchases and vulnerable to Pfizer's inventory management decisions.
Fiocruz non-compliance risk: Brazil Agreement states Fiocruz has not satisfied certain purchase commitments; company continues discussing steps to maximize sales but relies on government orders.
Israel geopolitical exposure: Facilities are in Israel amid ongoing military conflict; company mitigates by storing drug substance in multiple locations inside and outside Israel; deemed essential enterprise allowing emergency operations.
R&D spending acceleration: Q1 2026 R&D expenses up 56% YoY to $5.4M due to RELEASE study initiation; company expects significant, increasing R&D expenses ahead.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$33.8M

Net Income

Q1 2026

$18.3M

Free Cash Flow

Q1 2026

$21.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-1.2% YoY

$52.7MFY 2025

FY22 $47.6MFY23 $65.5MFY24 $53.4MFY25 $52.7M

Net Income

-325.2% YoY

$-6.6MFY 2025

FY22 $-14.9MFY23 $8.3MFY24 $2.9MFY25 $-6.6M

Operating Income

-240.4% YoY

$-5.5MFY 2025

FY22 $-13.0MFY23 $10.5MFY24 $3.9MFY25 $-5.5M

EPS (Diluted)

-300.0% YoY

$-0.08FY 2025

FY22 $-0.31FY23 $0.09FY24 $0.04FY25 $-0.08

Total Assets

+12.2% YoY

$82.3MFY 2025

FY22 $55.8MFY23 $84.4MFY24 $73.4MFY25 $82.3M

Op. Cash Flow

-238.3% YoY

$-12.0MFY 2025

FY22 $-25.0MFY23 $-1.3MFY24 $8.7MFY25 $-12.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$52.7M -1.2%	$53.4M -18.5%	$65.5M +37.5%	$47.6M -24.3%	$62.9M +15.0%	$54.7M
Net Income	$-6.6M -325.2%	$2.9M -64.7%	$8.3M +155.7%	$-14.9M -128.8%	$-6.5M +64.3%	$-18.3M
Operating Income	$-5.5M -240.4%	$3.9M -62.6%	$10.5M +180.4%	$-13.0M -580.2%	$2.7M +125.3%	$-10.7M
EPS (Diluted)	$-0.08 -300.0%	$0.04 -55.6%	$0.09 +129.0%	$-0.31 -40.9%	$-0.22 +82.1%	$-1.23
Total Assets	$82.3M +12.2%	$73.4M -13.0%	$84.4M +51.4%	$55.8M -17.9%	$67.9M +49.7%	$45.4M
Operating Cash Flow	$-12.0M -238.3%	$8.7M +758.1%	$-1.3M +94.7%	$-25.0M +4.2%	$-26.1M -34.9%	$-19.4M

AI Insight: PLX Financial Trends

Q1 2026 shows dramatic revenue acceleration to $34M and return to strong profitability with $18M net income, breaking a volatile 2025 trend.

• Revenue surged 89% from Q4 2025 ($9M) to Q1 2026 ($34M), largest quarterly jump in dataset.

• Operating income rebounded to $21M in Q1 2026 from $-5M in Q4 2025; operating margin reached 62%.

• Operating cash flow turned decisively positive at $22M in Q1 2026 after four consecutive quarters of negative or minimal OCF.

⚠ 2025 was volatile: revenue ranged $9M–$18M, earnings swung from $-4M to $6M. Sustainability of Q1 2026 spike unclear.

⚠ Equity grew 66% from Q2 2024 ($29M) to Q1 2026 ($67M), but debt figures unavailable to assess leverage changes.

AI Insight: PLX Ratio Trends

Protalix swung to 62.6% operating margin in Q1 2026 after severe Q4 2025 loss, but extreme quarterly volatility masks underlying business instability.

• Operating margin rebounded sharply to 62.6% in Q1 2026 from -51.1% in Q4 2025; net profit margin recovered to 54.3% from -60.3%.

• TTM operating margin solidly positive at 25.9% with 20.1% net margin and 29.4% ROIC, reflecting improved recent quarter performance.

• Last four quarters show violent swings: Q1 2025 OpMargin -41.0%, Q4 2025 -51.1%, interspersed with strong Q4 2024 at 39.6%.

⚠ Quarterly profitability is highly erratic with no clear seasonal pattern; Q1 2026 strength may not persist given recent volatility history.

⚠ D/E ratio missing for all periods; leverage profile unknown, limiting balance sheet risk assessment.

Get alerted when PLX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Protalix BioTherapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PLX

BlackRock, Inc.
$7.8M3,616,962 sh
MAK CAPITAL ONE LLC
$7.7M3,544,139 sh
RENAISSANCE TECHNOLOGIES LLC
$2.7M1,224,800 sh
STATE STREET CORP
$2.1M972,815 sh
NORTHERN TRUST CORP
$1.9M885,448 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.9M865,298 sh
Stratos Wealth Partners, LTD.
$1.1M500,000 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$938.5K432,485 sh
Prospera Financial Services Inc
$908.3K418,570 sh
Opaleye Management Inc.
$737.8K340,000 sh

Fund	Value	Shares
BlackRock, Inc.	$7.8M	3,616,962
MAK CAPITAL ONE LLC	$7.7M	3,544,139
RENAISSANCE TECHNOLOGIES LLC	$2.7M	1,224,800
STATE STREET CORP	$2.1M	972,815
NORTHERN TRUST CORP	$1.9M	885,448
GEODE CAPITAL MANAGEMENT, LLC	$1.9M	865,298
Stratos Wealth Partners, LTD.	$1.1M	500,000
VANGUARD PORTFOLIO MANAGEMENT LLC	$938.5K	432,485
Prospera Financial Services Inc	$908.3K	418,570
Opaleye Management Inc.	$737.8K	340,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PLX on your watchlist

Track score changes the day Protalix BioTherapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PLX a good stock to buy?

13F Pro's AI-powered analysis of Protalix BioTherapeutics, Inc. (PLX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PLX are available on the PLX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PLX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PLX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Protalix BioTherapeutics, Inc.'s investment landscape.